Oesophageal cancer is the eighth most common cancer worldwide with a 5-year survival rate of \<20% ([@bib5]). Malnutrition affects up to 80% of the patients and is multifactorial in aetiology ([@bib19]). Patients often present late with obstructive symptoms, cachexia, weight loss due to locally advanced disease. The psychological impact of diagnosis can result in low mood and depression, which may further reduce appetite ([@bib24]).

Definitive chemoradiotherapy (dCRT) is a treatment option for localised oesophageal cancer, particularly in squamous cell carcinoma or in patients with adenocarcinoma deemed unsuitable for surgery ([@bib11]; [@bib21]; [@bib6]; [@bib16]; [@bib2]; [@bib7]). Nearly half of the patients experience grade 3--4 gastrointestinal toxicities during dCRT ([@bib7]) and 20% may require invasive nutritional support ([@bib10]). Nutritional intervention improves weight gain, performance status, tolerability of treatment, overall survival (OS) and quality of life in oncology patients ([@bib13]). However prospective studies specifically evaluating the impact of malnutrition and nutritional intervention in patients with oesophageal cancer treated with dCRT are lacking.

The SCOPE1 (Study of Chemoradiotherapy in OesoPhageal Cancer with or without Erbitux) trial was a randomised controlled phase II/III trial comparing cisplatin-capecitabine-based dCRT for oesophageal cancer with or without cetuximab ([@bib7]). Two hundred and fifty eight patients were recruited from 36 centres in the UK between February 2008 and January 2012; the trial was stopped at the phase II stage because it met criteria for futility. The study reported an OS detriment in the cetuximab arm (22.1 months (95% CI 15.1--24.5) *vs* 25.4 months (95% CI 20.5--37.9); adjusted HR 1.53 (95% CI 1.03--2.27); *P*=0.035).

The aim of this study was to identify nutritional prognostic factors and the survival outcome of nutritional interventions in patients recruited to SCOPE1. We hypothesised that poor nutritional status at baseline would be associated with worse outcomes and nutritional intervention may improve survival.

Materials and methods
=====================

Study design
------------

Patients were randomised in a 1 : 1 allocation ratio. The control arm received four cycles of chemotherapy with cisplatin (60 mg m^−2^ IV day 1 of 21) and capecitabine (625 mg m^−2^ po bd, continuously). Concurrent conformal radiotherapy (50 Gy in 25 fractions over 5 weeks, 2 Gy per fraction) started with cycle 3 (week 7). In the research arm, cetuximab was commenced with cycle 1 (400 mg m^−2^ day 1 of week 1, then 250 mg m^−2^ weekly thereafter for 11 weeks).

The full trial protocol has been published elsewhere and was approved by the UK Medicines and Healthcare Products Regulatory Agency and a multicentre research ethics committee ([@bib12]). The SCOPE1 trial was an International Standard Randomised Controlled Trial, number 47718479. Written informed consent was obtained from all recruited patients.

Data collection
---------------

Data on the following nutritional parameters were prospectively collected at two time points, baseline and prior to dCRT (week 7): albumin (g l^−1^), body mass index (BMI, weight (kg) per height^2^ (metres)), Mellow score for dysphagia (grade 0--4) ([@bib15]), performance status (0--1) and nutritional intervention received (none, dietary advice, oral supplements or major intervention). Major intervention was defined as enteral feeding via nasogastric/nasojejunal tube placement, percutaneous endoscopic gastrostomy (PEG) or jejunostomy.

Due to difficulties in ascertaining usual body weight in cancer patients, the Lorentz formula was used to calculate ideal body weight ([@bib3]). Percentage weight loss was defined as ((current body weight−ideal body weight)/ideal body weight) × 100. The nutritional risk index (NRI) was calculated at each time point using the following formula: NRI=(1.519 × albumin g dl^−1^) + 41.7(present weight/ideal weight) ([@bib4]; [@bib22]; [@bib1]). Patients were stratified according to the risk of malnutrition: NRI score ⩾100: no risk; NRI 97.5--100: mild risk; NRI 83.5--97.5: moderate risk; NRI\<83.5: major risk.

Cross tabulations of median survival were generated for all effect modifiers and compared independently with the NRI and study design stratification variables (treatment as allocated, centre, type of tumour, stage, reason for non-surgical therapy, age, gender, baseline weight and dysphagia score).

Statistical analysis
--------------------

The main analysis determined the effect modifiers of survival using a multivariable model at baseline. Cox proportion hazards regression was used to model survival. As trial participants were recruited from 36 centres, treatment centre was included as a frailty to adjust for clustering.

The baseline Cox proportion hazards model included variables consistent with the main trial analysis as *a priori* prognostic variables (centre, disease stage, reason for no surgery, tumour type (adenocarcinoma *vs* squamous histology), tumour stage, trial arm, performance status, sex, tumour length, radiation dose, cisplatin dose, capecitabine dose and age group). Additional justified effect modifiers (including biochemistry and nutritional parameters) were tested for inclusion in the base model. The main effects of these modifiers and the pre-specified interactions were sequentially introduced in order of statistical importance using a likelihood ratio test (*P*⩽0.01) independently for each time point (baseline and pre-dCRT). Parameter estimates, standard errors and *P* values were calculated. The proportional hazards assumption was assessed visually using Kaplan-Meier plots. Non-parametric log-rank tests were used to assess differences in hazard functions across subgroups.

Results
=======

Data from 258 patients recruited to the SCOPE1 trial were evaluated; details of the main analysis are published elsewhere ([@bib7]). The median length of follow-up was 25.0 (IQR 12.6-42.7) months. The number of patients in each NRI group at baseline was balanced between the two treatment arms (dCRT alone *vs* dCRT plus cetuximab, data not shown).

The majority of patients were classified not at risk of malnutrition (NRI⩾100) at baseline (217 (84%) patients); 14 (5%) were at mild risk (NRI 97.5--100), 22 (9%) at moderate risk (NRI 83.5--97.5) and only 5 (2%) were calculated to be at major risk (NRI\<83.5). However, after 6 weeks of induction chemotherapy the number of patients at moderate/major malnutrition risk had increased (179 patients (70%), no risk; 16 (6%), mild risk; 48 (19%), moderate risk; 11 (4%), major risk).

The number of patients receiving nutritional intervention increased during induction chemotherapy (143 (56%) patients at baseline *vs* 192 (75%) patients prior to dCRT). Although the number of patients receiving dietary advice alone remained approximately stable (44 (17%) *vs* 40 (16%) patients), the use of oral supplements (74 (29%) *vs* 110 (43%) patients) and feeding tubes increased on treatment (25 (10%) *vs* 42 (16%) patients).

Median OS for patients according to NRI score and nutritional intervention received at baseline and prior to dCRT are shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. Tumour length (6--8 cm), stage III disease and receiving \<50 Gy radiotherapy were identified as independent prognostic factors in multivariable analysis (*P*\<0.01), ([Table 3](#tbl3){ref-type="table"}).

Overall survival was significantly worse in patients classified to be at the risk of malnutrition at baseline (NRI\<100, median survival time 15.7 months; IQR 7.4--25.8) compared with patients not at risk (NRI⩾100, median survival time 31.6 months; IQR 14.7--58.0) (HR 12.5 (95% CI 5.2--29.6), *P*\<0.001) ([Figure 1](#fig1){ref-type="fig"}). In these at-risk patients, providing nutritional intervention at baseline was associated with an improved OS (dietary advice (HR 0.12 (0.03--0.51), *P*=0.004), oral supplements (HR 0.13, (0.04--0.39), *P*\<0.001) and major intervention (HR 0.13 (0.03--0.50), *P*=0.003) ([Table 3](#tbl3){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}). Univariable main effects not included in the multivariable model are shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

The median survival for patients with NRI\<100 and NRI⩾100 prior to starting dCRT was 15.4 and 30.3 months, respectively, but after adjustment for other factors this was not significant in the multivariable model (HR 1.79 (0.64--5.04), *P*=0.27, full model not shown). Furthermore, nutritional intervention provided to at-risk patients after the commencement of induction chemotherapy was no longer associated with a survival benefit (dietary advice alone HR 1.31, *P*=0.72; oral supplements HR 0.86, *P*=0.81; major intervention HR 0.84, *P*=0.81).

The only survival difference based on nutritional parameters between the trial arms was seen in patients who required major nutritional intervention; those allocated to dCRT plus cetuximab had a shorter OS than those treated with dCRT alone at both baseline (HR 4.7 (1.4--15.70), *P*=0.01) and pre-dCRT (HR 5.4 (1.75--16.36), *P*=0.003).

Discussion
==========

This study suggests that increased nutritional risk at baseline is associated with reduced survival in patients with localised oesophageal cancer treated with dCRT. An NRI score \<100 strongly predicted for reduced OS. An improvement in survival was observed following baseline nutritional intervention with dietary advice, oral supplementation or major intervention. A similar benefit was not observed if nutritional intervention occurred later in the treatment course.

To our knowledge this is the first evaluation of prospectively collected data to demonstrate the benefit of nutritional intervention in oesophageal cancer. Other groups have identified prognostic nutritional factors in patients treated with dCRT. [@bib23] performed recursive partitioning analysis of pre-treatment variables in 416 patients; only pre-treatment weight loss \>10% in the 6 months prior to treatment was identified as a significant factor. BMI\>18 kg m^−2^, Atkinson dysphagia score *\<*2, dose of RT\>50 Gy and complete response to CRT were found to be independent prognostic factors for survival in a retrospective analysis of 105 patients ([@bib8]). In a more recent study by the same group, OS was 25 months in patients with persistent malnutrition compared with 42 months in those who remained well nourished during CRT ([@bib9]). There is also evidence for nutritional factors as predictors of benefit following dCRT. [@bib8] found a significant difference in baseline percentage weight loss, albumin level and BMI between responders and non-responders; response rates to dCRT were significantly lower in patients with malnutrition at baseline and during treatment.

Malnutrition in patients treated for oesophageal cancer is common and may be related to the disease or its treatment ([@bib17]). Appropriate nutritional support is important for maintaining treatment intensity and may influence outcome ([@bib13]). A formalised nutritional pathway for patients receiving dCRT significantly reduced complications with less weight loss, fewer unplanned hospital admissions and greater radiotherapy completion rates observed ([@bib18]). Concerns regarding the use of PEG feeding tubes in oesophageal cancer relating to safety of dilatation and potential for inoculation metastasis have been raised ([@bib20]). However in a retrospective analysis, PEG placement was successful in the majority of patients prior to multimodality treatment for oesophageal cancer and was significantly related to attainment of target doses of chemoradiotherapy (*P*=0.034), and survival at 12 months (*P*=0.02) ([@bib14]). In our study, patients with NRI⩾100 at baseline requiring major nutritional intervention had a worse outcome than those who required no nutritional support (24.7 *vs* 34.5 months, [Table 1](#tbl1){ref-type="table"}). This may represent patients with significant dysphagia at presentation due to more locally advanced disease and subsequent reduced survival rates. For patients with mild (NRI 97.5--100) or moderate/major (NRI\<97.5) risk, major nutritional intervention improved survival (7.4 *vs* 44 months and 3.5 *vs* 10.6 months, respectively, [Table 1](#tbl1){ref-type="table"}).

Patients allocated to cetuximab arm who required a major nutritional intervention at baseline had worse survival rates compared with controls (13.3 *vs* 28 months); a similar finding was observed if nutritional intervention occurred prior to dCRT (13.3 *vs* 31.1 months). The cause for this survival difference is unclear and based on small patient numbers, however, one hypothesis is that fewer patients receiving cetuximab completed the standard protocol treatment, with significant differences in the number of chemotherapy cycles received and total radiotherapy dose delivered ([@bib7]).

Our study has limitations; first, only 16% of the patients were deemed at risk of malnutrition at baseline, which is lower than anticipated. This may represent selection bias as only patients with performance status 0--1 were recruited, or an inadequacy in dietetic screening as formal dietetic assessment was not a trial prerequisite. Second, although the nutritional data were collected prospectively, the analysis itself is retrospective and requires further prospective validation. Third, although data on whether patients received nutritional intervention were collected, the details of the intervention, intensity of dietetic follow-up or variation between centres were not collected. A randomised control trial of 'conventional hospital protocol nutritional intervention\' *vs* 'NRI-directed nutritional intervention\' may be required to assess the true value of NRI-directed intervention in this patient group.

In conclusion, assessment and correction of poor nutritional state at baseline may be a simple and cost-effective intervention that improves survival outcomes in oesophageal cancer patients treated with dCRT. Nutritional Risk Index serves as a simple and objective screening tool to identify patients at risk of malnutrition. In this study, the benefit of nutritional intervention was no longer observed once treatment had commenced, highlighting the need for early nutritional assessment and intervention.
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![Kaplan-Meier curve of overall survival for patients with baseline NRI\<100 according to nutritional intervention received at baseline (log-rank *P*=0.001). Abbreviation: NRI, nutritional risk index.](bjc2016129f2){#fig2}

###### Median survival time (months) according to maximum nutritional intervention received and nutritional risk index (NRI) score at baseline

                                    **NRI score**                          
  -------------------------------- --------------- ----------- ----------- ------------
  None                               34.5 (105)      7.4 (3)     3.5 (6)    29.2 (114)
  Dietary advice                      31.6 (39)     28.8 (2)    18.4 (3)    28.9 (44)
  Oral supplements                    24.6 (58)     23.9 (5)    19.1 (11)   23.4 (74)
  Major nutritional intervention      24.7 (15)     44.0 (4)    10.6 (6)    23.6 (25)
  All patients                       27.9 (217)     21.1 (14)   11.3 (21)   24.9 (257)

Data on nutritional intervention received at baseline were missing for one patient.

###### Median survival time (months) according to maximum nutritional intervention received and nutritional risk index (NRI) score prior to definitive chemoradiotherapy (dCRT)

                                    **NRI score**                          
  -------------------------------- --------------- ----------- ----------- ------------
  None                                35.7 (56)     23.1 (9)    11.3 (1)    35.1 (66)
  Dietary advice                      36.7 (29)     12.2 (10)               35.9 (39)
  Oral supplements                    24.8 (74)     19.1 (29)   11.3 (6)    23.2 (109)
  Major nutritional intervention      24.7 (20)     16.5 (16)   13.0 (4)    21.4 (40)
  All patients                       30.2 (179)     18.3 (64)   12.5 (11)   24.9 (254)

Data on NRI score prior to dCRT were missing for four patients.

###### Univariable and multivariable analysis of baseline prognostic factors of overall survival

                                                                     **Survival**        **Univariable analysis**   **Multivariable analysis**                        
  ------------------------------------------------------------ ------------------------ -------------------------- ---------------------------- --------------------- ---------
  Age                                                                                                                                                                 
  \<70 years                                                     160, 26.2 (43--14.3)           Reference                   Reference                                 
  ⩾70 years                                                      98, 22.6 (40.3--9.2)       1.33, (0.98--1.81)                0.068              1.19, (0.82--1.72)     0.366
  Gender                                                                                                                                                              
  Male                                                           145, 24 (38.6--11.3)       1.47, (1.07--2.00)                0.016              1.38, (0.95--2.02)     0.095
  Female                                                        113, 26.1 (46.9--14.3)          Reference                   Reference                                 
  Performance status                                                                                                                                                  
  0                                                              131, 27.2 (44--14.7)           Reference                   Reference                                 
  1                                                              127, 24.5 (40.3--10)       1.17, (0.86--1.59)                0.320              0.96, (0.67--1.39)     0.833
  Tumour length                                                                                                                                                       
  \<2 cm                                                        56, 30.7 (46.4--12.1)           Reference                   Reference                                 
  2--4 cm                                                       85, 30.3 (46.9--14.8)       1.00, (0.63--1.57)                0.992              1.16, (0.70--1.89)     0.568
  4--6 cm                                                       55, 24.9 (42.4--11.5)       1.48, (0.93--2.36)                0.102              1.40, (0.79--2.47)     0.250
  6--8 cm                                                        62, 18.2 (35.9--10)        1.87, (1.18--2.96)                0.008              1.81, (1.05--3.12)     0.034
  Stage                                                                                                                                                               
  I+II                                                          103, 35.9 (46.6--15.3)          Reference                   Reference                                 
  III                                                            155, 23.2 (37--11.3)       1.66, (1.20--2.30)                0.002              1.58, (1.05--2.38)     0.027
  Tumour type                                                                                                                                                         
  Squamous cell                                                 188, 25.4 (43.3--13.6)          Reference                   Reference                                 
  Adenocarcinoma                                                70, 23.2 (39.1--10.2)       1.28, (0.92--1.78)                0.144              0.97, (0.62--1.52)     0.907
  Reason for no surgery                                                                                                                                               
  Patient choice                                                97, 26.7 (46.6--14.7)           Reference                   Reference                                 
  Comorbidity                                                   36, 31.6 (42.7--11.1)       1.24, (0.79--1.94)                0.350              0.93, (0.51--1.70)     0.817
  Local extent                                                   122, 24 (40.6--11.5)       1.20, (0.86--1.69)                0.285              0.87, (0.58--1.29)     0.478
  Treatment arm                                                                                                                                                       
  dCRT only                                                     129, 23.3 (39.4--10.2)                                                                Reference       
  dCRT + cetuximab                                               129, 27.8 (46--14.8)       1.27, (0.94--1.71)                0.125              0.82, (0.49--1.37)     0.440
  Full radiation protocol dose                                                                                                                                        
  Yes                                                            217, 30.1 (46--14.9)           Reference                   Reference                                 
  No                                                             41, 8.2 (20.8--2.9)        3.46, (2.36--5.07)               \<0.001             2.92, (1.49--5.75)     0.002
  \% of full cisplatin protocol dose                                                                                                                                  
  ⩾95%                                                          106, 35.2 (46.9--16.9)          Reference                   Reference                                 
  ⩾75--\<95%                                                     76, 29 (44.3--15.3)        1.29, (0.88--1.90)                0.184              1.11, (0.70--1.75)     0.672
  ⩾50--\<75%                                                     41, 18.4 (36--12.5)        2.20, (1.44--3.38)               \<0.001             1.76, (1.00--3.13)     0.051
  \<50%                                                          35, 10.2 (24.7--5.9)       3.17, (2.00, 5.03)               \<0.001             1.80, (0.86--3.76)     0.118
  \% of full capecitabine protocol dose                                                                                                                               
  ⩾95%                                                          82, 32.8 (45.3--14.9)           Reference                   Reference                                 
  ⩾75--\<95%                                                    90, 28.1 (45.9--14.8)       1.07, (0.73--1.59)                0.719              0.99, (0.62--1.58)     0.956
  ⩾50--\<75%                                                     52, 22.5 (43.3--7.7)       1.58, (1.03--2.41)                0.035              0.97, (0.54--1.73)     0.907
  \<50%                                                          34, 15.6 (23.2--5.9)       2.34, (1.46--3.76)               \<0.001             0.73, (0.32--1.69)     0.465
  NRI                                                                                                                                                                 
  ⩾100                                                           217, 28 (45.9--14.2)           Reference                   Reference                                 
  \<100                                                           41, 15.6 (24.5--8)        2.26, (1.54--3.30)               \<0.001             12.45, (5.24--29.6)   \<0.001
  Nutritional intervention                                                                                                                                            
  None                                                          114, 29.2 (46.8--12.8)                                                                Reference       
  Dietary advice alone                                           44, 29 (44.6--15.7)        1.05, (0.67--1.63)                0.835              1.18, (0.59--2.39)     0.638
  Oral supplements                                              74, 23.4 (35.8--10.9)       1.49, (1.04--2.15)                0.030              1.00, (0.54--1.85)     0.992
  Major intervention                                             25, 23.7 (40.3--10)        1.20, (0.69--2.08)                0.525              0.53, (0.19--1.50)     0.232
  Nutritional intervention in the CRT + cetuximab group                                                                                                               
  None                                                                                                                                                Reference       
  Dietary advice alone                                                                                                                           1.19, (0.45--3.15)     0.720
  Oral supplements                                                                                                                               1.94, (0.89--4.20)     0.093
  Major intervention                                                                                                                             4.69, (1.40--15.7)     0.012
  Nutritional intervention in those with a baseline NRI\<100                                                                                                          
  None                                                                                                                                                Reference       
  Dietary advice alone                                                                                                                           0.12, (0.03--0.51)     0.004
  Oral supplements                                                                                                                               0.13, (0.04--0.39)    \<0.001
  Major intervention                                                                                                                             0.13, (0.03--0.50)     0.003

Abbreviations: CI=confidence interval; CRT=chemoradiotherapy; dCRT=definitive chemoradiotherapy; HR=hazard ratio; NRI=nutritional risk index.
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